Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03025542) involved 49 people with psoriasis who were split into two groups: 32 received bimekizumab 320 mg alongside a placebo (a dummy treatment with no active ingredient), and 17 received bimekizumab 320 mg on its own. Of those who started, 30 and 15 participants respectively completed the study. The trial was measuring two main things: how psoriasis severity scores changed over 28 weeks, and how much of the study drug was present in participants' blood at various points in time. The reported data shows that psoriasis severity was measured using a standard scoring tool called the PASI (Psoriasis Area and Severity Index), which runs from 0 to 72, where a higher number means more severe psoriasis. By week 28, the group receiving bimekizumab alongside a placebo had an average score change of −10.76 points from where they started, while the group receiving bimekizumab alone had an average change of −19.74 points. A negative number means scores went down (i.e. moved toward less severe) from the starting point. Regarding the amount of drug measured in the blood, the reported data shows no figures were available at the starting point (baseline) for either group. At week 2, average blood levels were 19.749 micrograms per millilitre in the placebo-combination group and 14.437 in the bimekizumab-alone group. These levels shifted at later time points — at week 4, week 8, and week 12 — with figures ranging roughly between 5 and 17 micrograms per millilitre across both groups, as detailed in the full results. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 34687214) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Psoriasis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 70 years old
- You have had chronic plaque psoriasis for at least 6 months before the screening visit
- Your psoriasis is rated as moderately severe or worse based on standard medical scoring tools that measure the area and severity of your skin condition (confirm with trial site)
- Your doctor has considered you a candidate for systemic (whole-body) psoriasis treatments, light therapy, or a combination of light and medication therapy
- If you are a woman who could become pregnant, you must be willing to use a highly effective form of birth control until 20 weeks after your last dose of the study drug, and have a negative pregnancy test at the start of the trial
- If you are a woman who cannot become pregnant due to menopause or permanent sterilisation, you are also eligible to apply
- If you are a man whose partner could become pregnant, you must be willing to use a condom during sex until 20 weeks after your last dose of the study drug
Who may not be able to join:
- You have previously taken part in a study involving the drug bimekizumab
- You have a specific type of psoriasis such as the full-body redness type, the drop-shaped type, the pus-filled type, or psoriasis caused by a medication
- You have a history of repeated or long-lasting infections, or had a serious infection (including shingles) in the 6 months before the baseline visit
- Your doctor believes you are at high risk of getting an infection
- You currently have any signs or symptoms that could suggest an active infection
- You have hepatitis B, hepatitis C, or HIV
- You have received a live or live-attenuated vaccine in the 8 weeks before the baseline visit
- You currently have cancer or have been diagnosed with cancer in the last 5 years (some exceptions may apply — confirm with trial site)
- You have a condition that weakens your immune system as a primary diagnosis
- You have tuberculosis (TB), are at high risk of getting TB, have a latent (inactive) TB infection, or have a history of a related type of bacterial infection (confirm with trial site)
- You have abnormal results on certain laboratory tests as defined by the study (confirm with trial site)
- Your doctor feels there is any other reason you would not be suitable for this trial
- You have been treated with more than one biologic medicine of a specific type, or have used any biologic medicine in the three months before the baseline visit (confirm with trial site)
- You have previously been treated with any anti-IL-17 therapy for psoriasis or psoriatic arthritis
- You have been diagnosed with another inflammatory condition such as rheumatoid arthritis, sarcoidosis, or lupus (note: people with Crohn's disease or ulcerative colitis may still be eligible if their condition is not currently active — confirm with trial site)
- You are currently taking medications for psoriatic arthritis other than standard painkillers or anti-inflammatory drugs
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: UCB Cares, 001 844 599 2273(UCB)
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change From Baseline in Psoriasis Area and Severity Index (PASI) at Week 28; Plasma Concentration of Bimekizumab at Baseline; Plasma Concentration of Bimekizumab at Week 2; Plasma Concentration of Bimekizumab at Week 4; Plasma Concentration of Bimekizumab at Week 8; Plasma Concentration of Bimekizumab at Week 12; Plasma Concentration of Bimekizumab at Week 16; Plasma Concentration of Bimekizumab at Week 20; Plasma Concentration of Bimekizumab at Week 24; Plasma Concentration of Bimekizumab at Week 28; Plasma Concentration of Bimekizumab at Week 36; Percentage of Participants Reporting Positive...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.